Physicians' Academy for Cardiovascular Education

More insight into effects of treatment with PCSK9 inhibition from 5 new FOURIER analyses

Nov. 14, 2017 - Anaheim, CA, USA - Robert Giugliano - Boston, MA, USA

Robust benefits for CV and limb event risk in PAD patients on PCSK9 inhibition

Nov. 13, 2017 - AHA 2017 - Anaheim, CA - Marc Bonaca - Boston, MA, USA

Greater relative and absolute risk reduction in high-risk subgroup with previous MI treated with PCSK9 inhibition

Nov. 13, 2017 - AHA 2017 - Anaheim, CA - Marc Sabatine - Boston, MA, VS

PCSK9 inhibition & CV events: Review of recent and upcoming hard endpoint outcome trials

Aug. 26, 2017 - Barcelona, Spain - Peter Sever, MD London, United Kingdom - PACE-CME symposium at ESC 2017

PCSK9 inhibition across a wide spectrum of patients: One size fits all?

Aug. 26, 2017 - Barcelona, Spain - G. Kees Hovingh, MD, AMC, Amsterdam, The Netherlands - PACE-CME symposium at ESC 2017

Diverse study data confirm the rationale of intensive lipid-lowering

Aug. 29, 2017 - Christie Ballantyne - Houston, Texas, VS

Imaging components of plaque not more informative than burden of plaque

Aug. 30, 2017 - Stephen Nicholls, MD, Adelaide, Australia

Understanding new PCSK9 outcome data: From the LDL-C hypothesis to LDL-c causality

Aug. 26, 2017 - ESC 2017, Barcelona, Spain - John Chapman, PhD, Paris, France - PACE-CME symposium

Achieving very low LDL-c levels (<0.5 mmol/L or <20 mg/dL) with PCSK9 inhibition is safe and effective

Aug. 28, 2017

LDL-c still reduced after 1 year with siRNA against PCSK9

Aug. 28, 2017

PCSK9 inhibition works, but you can’t force biology

Mar. 17, 2017 - Prof. Wouter Jukema – Leiden University Medical Center, The Netherlands - ACC 2017, Washington DC, USA

Landmark study with PCSK9 inhibitor will change clinical practice

Mar. 18, 2017 - Prof. Eric Bruckert - Pitié-Salpêtrière Hospital, Paris, France - ACC 2017, Washington DC, USA

Changing therapeutic behaviour after FOURIER

Mar. 18, 2017 - Prof. Wolfgang Koenig - Munich, Germany - ACC 2017, Washington DC, USA

The implications of PCSK9 outcome trials for GPs

Mar. 19, 2017 - Prof. Richard Hobbs – Oxford, United Kingdom - ACC 2017, Washington DC, USA

PCSK9 inhibitors: From bench to bedside

Mar. 17, 2017 - Prof. Gilles Lambert – Sainte-Clotilde, France - ACC 2017, Washington DC, USA

The longer you treat, the better the benefit: lessons from PCSK9 inhibitors trials

Mar. 19, 2017 - Prof. Stephen J. Nicholls - Adelaide, Australia - ACC 2017, Washington DC, USA

Lowering LDL-c for a longer period of time really matters

Mar. 17, 2017 - Paul M. Ridker - Boston, MA, USA - ACC 2017, Washington DC, USA

No J-shaped curve for efficacy in PCSK9 outcome trials

Mar. 18, 2017 - Prof. Kausik Ray - London, United Kingdom - ACC 2017, Washington DC, USA

PCSK9 outcome trials: The results put into perspective of other clinical developments

Mar. 19, 2017 - Prof. Peter Sever - London, United Kingdom - ACC 2017, Washington DC, USA

LDL lowering for CVD prevention: From hypothesis to axiom

Mar. 19, 2017 - Prof. John JP Kastelein - Amsterdam, The Netherlands - ACC 2017, Washington DC, USA

Implications PCSK9 Outcome Trials: Should LDL-c targets in high-risk individuals be maintained or further lowered?

Mar. 18, 2017 - Prof. John Chapman - Paris, France - ACC 2017, Washington DC, USA

Humanised PCSK9 antibody lowers CV events in high-risk patients, but LDL-c lowering effects decline over time

Mar. 17, 2017

CV outcomes with a PCSK9 inhibitor: FOURIER study

Mar. 16, 2017

Careful implementation of PCSK9 inhibitors in clinical practice

Aug. 30, 2016 - ESC Rome, Italy - Prof. dr. Terje Pedersen (Oslo, Norway)

Promising results in pivotal trials of novel lipid-modifying drugs

Dec. 12, 2016 - Amsterdam, The Netherlands - Prof. John JP Kastelein, MD (AMC Amsterdam, The Netherlands)

Investigational epigenetic therapy lowers incidence of MACE in phase 2b study

Nov. 15, 2016 - AHA 2016, New Orleans, LA, USA - Dr. Norman Wong, Calgary, AB, Canada
##SCROLLER_ITEMS_FULL_TITLE##

New class of lipid-lowering medication shows lasting LDL-c lowering in dose-finding study

Nov. 22, 2016 - Kausik Ray, MD - Imperial College London, United Kingdom
##SCROLLER_ITEMS_FULL_TITLE##

Brief update on various pharmacotherapeutic strategies to lower CV risk

Nov. 21, 2016 - AHA 2016 - Prof. Wouter Jukema, MD (LUMC Leiden, The Netherlands)
##SCROLLER_ITEMS_FULL_TITLE##

PCSK9 inhibitor on top of statin therapy gives additional atheroma volume regression

Nov. 21, 2016 - AHA 2016 - Steve Nissen, MD (Cleveland Clinic, Cleveland, OH, USA)
##SCROLLER_ITEMS_FULL_TITLE##

Frequency apheresis lowered in FH patient receiving PCSK9-inhibiting treatment

Oct. 4, 2016 - ESC - 2016 Rome - Prof Patrick M Moriarty, MD (University of Kansas Medical Center, KS, USA)

More insight into effects of treatment with PCSK9 inhibition from 5 new FOURIER analyses

AHA 2017 - Anaheim, CA, USA

Nov. 14, 2017 - Anaheim, CA, USA - Robert Giugliano - Boston, MA, USA
Dr. Giugliano summarises findings of 2 additional clinical trial updates and studies into infarct size, TIMI stable IHD risk and total events in the FOURIER trial.

AHA 2017 Dr. Giugliano summarises findings of 2 additional clinical trial updates and studies into infarct size, TIMI stable IHD risk and total events in the FOURIER trial.

Robust benefits for CV and limb event risk in PAD patients on PCSK9 inhibition

AHA 2017 - Anaheim, CA

Nov. 13, 2017 - AHA 2017 - Anaheim, CA - Marc Bonaca - Boston, MA, USA
PAD patients enrolled in the FOURIER trial who were treated with PCKS9 inhibitor evolocumab showed a higher absolute and relative CV event reduction, and a large reduction in limb events.

AHA 2017 PAD patients enrolled in the FOURIER trial who were treated with PCKS9 inhibitor evolocumab showed a higher absolute and relative CV event reduction, and a large reduction in limb events.

Greater relative and absolute risk reduction in high-risk subgroup with previous MI treated with PCSK9 inhibition

AHA 2017 - Anaheim, CA, USA

Nov. 13, 2017 - AHA 2017 - Anaheim, CA - Marc Sabatine - Boston, MA, VS
Subanalysis of FOURIER shows that within the subgroup of patients with prior MI, a subgroup at extra high risk has greater benefit of LDL-c lowering with PCSK9 inhibitor evolocumab.

AHA 2017 Subanalysis of FOURIER shows that within the subgroup of patients with prior MI, a subgroup at extra high risk has greater benefit of LDL-c lowering with PCSK9 inhibitor evolocumab.

PCSK9 inhibition & CV events: Review of recent and upcoming hard endpoint outcome trials

Aug. 26, 2017 - Barcelona, Spain - Peter Sever, MD London, United Kingdom - PACE-CME symposium at ESC 2017
Lecture by Peter Sever, MD held at symposium on PCSK9 inhibition & Cardiovascular Outcomes:  Review of lipid targets and treatment strategies

This lecture was part of a CME accredited symposium: PCSK9 inhibition & Cardiovascular Outcomes: Review of lipid targets and treatment strategies held at ESC 2017 in Barcelona on August 26, 2017.

PCSK9 levels positively associated with outcomes in patients with worsening HF

Oct. 25, 2017 - Bayes-Genis A, et al. - J Am Coll Cardiol

In patients with WHF, risk was positively associated with PCSK9 levels and negatively with LDL-receptor levels, suggesting that PCSK9 inhibition might lead to better outcomes in HF.

ESC/EAS Task Force published update of clinical guidance for use of PCSK9 inhibitors

Oct. 17, 2017 - news

The practical clinical guidance aims to help clinicals identify very high risk patients with substantially elevated LDL-c despite treatment, who are likely to benefit most from treatment with PCSK9 inhibition

Long-term PCSK9 inhibitor safe and effective in HeFH

Oct. 5, 2017 - Hovingh GK et al. - J Clin Lipidol 2017

Long-term dosing of evolocumab in patients with heterozygous familial hypercholesterolemia is safe and well tolerated, and resulted in marked reduction of LDL-C levels.

PCSK9 inhibition across a wide spectrum of patients: One size fits all?

Aug. 26, 2017 - Barcelona, Spain - G. Kees Hovingh, MD, AMC, Amsterdam, The Netherlands - PACE-CME symposium at ESC 2017
Lecture by Prof Kees Hovingh held at symposium on PCSK9 inhibition & Cardiovascular Outcomes:  Review of lipid targets and treatment strategies

This lecture was part of a CME accredited symposium: PCSK9 inhibition & Cardiovascular Outcomes: Review of lipid targets and treatment strategies held at ESC 2017 in Barcelona on August 26, 2017

Clinical benefit of PCSK9 inhibition in diabetic patients on insulin at high CV risk

Sep. 26, 2017 - Leiter LA et al. - Diabetes Obes Metab. 2017

Alirocumab produced significant LDL-C reductions in individuals with T2DM or T1DM and with hypercholesterolemia at high CV risk receiving insulin.

Diverse study data confirm the rationale of intensive lipid-lowering

ESC 2017 - Barcelona

Aug. 29, 2017 - Christie Ballantyne - Houston, Texas, VS

ESC 2017 Dr. Christie Ballantyne summarises results of diverse studies into various lipid lowering therapies, both approved and experimental strategies, and concludes that they all reinforce current guidelines.

Imaging components of plaque not more informative than burden of plaque

ESC 2017 Barcelona

Aug. 30, 2017 - Stephen Nicholls, MD, Adelaide, Australia
Virtual histology of components of plaque does not provide additional information in the serial imaging GLAGOV study that showed more coronary atherosclerosis regression when PCSK9 inhibitor evolocumab was added to intensive statin-treatment.

ESC 2017 Virtual histology of components of plaque does not provide additional information in the serial imaging GLAGOV study that showed more coronary atherosclerosis regression when evolocumab was added to intensive statin-treatment.

Understanding new PCSK9 outcome data: From the LDL-C hypothesis to LDL-c causality

Aug. 26, 2017 - ESC 2017, Barcelona, Spain - John Chapman, PhD, Paris, France - PACE-CME symposium

This lecture was part of a CME accredited symposium: PCSK9 inhibition & Cardiovascular Outcomes: Review of lipid targets and treatment strategies held at ESC 2017 in Barcelona on August 26, 2017